What this means
This is a trial that is still signing up people, so no results exist yet. It will check whether metformin is safe and whether it may protect the brain over nine months.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 55–75
- Where
- 1 site, including New York
The science
- Registered title
- Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
- Trial ID
- NCT06463743 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Multiple Sclerosis
- What is tested
- metformin, Placebo
- Sponsor
- State University of New York at Buffalo
- Ages
- 55 Years to 75 Years
- Dates
- First posted Jun 18, 2024 · updated Nov 21, 2025
Registry summary
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn:
- The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo
- How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period
- The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
Sites (1)
- UBMD Neurolgy, Buffalo, New York, United States